Skip to main content

and
  1. Article

    Open Access

    Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

    The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D...

    Vania Hungria, Deborah M. Martínez-Baños, María-Victoria Mateos in Advances in Therapy (2020)